• IDEAYA Biosciences entered a clinical collaboration with Roche to test IDE892 with Roche’s RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer.
• IDEAYA will sponsor the Phase 1 combination study; Roche will supply RG6505; joint governance will oversee the trial.
• Companies kept commercial rights to their respective drugs, including use as monotherapy or in combinations.
• Collaboration allows a potential triplet study adding IDE397, subject to joint approval.
• MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma, a key target population for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606030600PR_NEWS_USPR_____SF73390) on June 03, 2026, and is solely responsible for the information contained therein.